Filing Flows › Orchestra BioMed Holdings (OBIO) › Stock forecast & fair value
Orchestra BioMed Holdings (OBIO) stock forecast and price target
Orchestra BioMed Holdings (OBIO) trades at $5.68. 7 analysts' median price target is $11.00 (+94%), from $9.00 to $20.00.
Orchestra BioMed Holdings' latest quarter
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for OBIO stock?
The median of 7 analysts' 12-month targets is $11.00, +94% from $5.68; the range is $9.00 to $20.00. The average rating is strong buy.
Does Orchestra BioMed Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is OBIO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.